The Fifth-Gen CRISPR Pivot: From Artisanal Cure to Industrial Medicine

The clinical validation of fifth-generation CRISPR in 2026 marks the definitive collapse of the bespoke therapeutic paradigm, shifting biotechnology from high-cost, low-volume miracles to scalable pharmaceutical infrastructure with a 96.3% remission rate across 847 patients.